Chenguang Wang

List of Publications by Year in Descending Order

58 papers	761 citations	15 h-index	25 g-index
60 ext. papers	1,028 ext. citations	4.4 avg, IF	5.04 L-index

#	Paper	IF	Citations
58	Simultaneous improvement of physical stability, dissolution, bioavailability, and antithrombus efficacy of Aspirin and Ligustrazine through cocrystallization.. *International Journal of Pharmaceutics*, **2022**, 121541	6.5	2
57	Mechanisms of Crystal Plasticization by Lattice Water.. *Pharmaceutical Research*, **2022**, 1	4.5	0
56	Effect of deaeration on processability of poorly flowing powders by roller compaction.. *International Journal of Pharmaceutics*, **2022**, 621, 121803	6.5	
55	Effects of shear cell size on flowability of powders measured using a ring shear tester. *Powder Technology*, **2021**, 396, 555-555	5.2	2
54	MOF-Derived hierarchical porous 3D ZnO/Ag nanostructure as a reproducible SERS substrate for ultrasensitive detection of multiple environmental pollutants.. *Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy*, **2021**, 270, 120818	4.4	5
53	Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion. *International Journal of Pharmaceutics*, **2021**, 610, 121216	6.5	0
52	Improving the Solubility, Dissolution, and Bioavailability of Metronidazole via Cocrystallization with Ethyl Gallate. *Pharmaceutics*, **2021**, 13,	6.4	3
51	Drug□Drug Cocrystallization Simultaneously Improves Pharmaceutical Properties of Genistein and Ligustrazine. *Crystal Growth and Design*, **2021**, 21, 3461-3468	3.5	1
50	Effects of compaction and storage conditions on stability of intravenous immunoglobulin - Implication on developing oral tablets of biologics. *International Journal of Pharmaceutics*, **2021**, 604, 120737	6.5	1
49	Structural Insights into the Distinct Solid-State Properties and Interconversion of Celecoxib N-Methyl-2-pyrrolidone Solvates. *Crystal Growth and Design*, **2021**, 21, 277-286	3.5	3
48	Reversible facile single-crystal-to-single-crystal polymorphic transition accompanied by unit cell volume expansion and twinning. *CrystEngComm*, **2021**, 23, 2648-2653	3.3	1
47	Sweet Sulfamethazine Acesulfamate Crystals with Improved Compaction Property. *Crystal Growth and Design*, **2021**, 21, 1077-1085	3.5	2
46	Structural Origins of Elastic and 2D Plastic Flexibility of Molecular Crystals Investigated with Two Polymorphs of Conformationally Rigid Coumarin. *Chemistry of Materials*, **2021**, 33, 1053-1060	9.6	15
45	Modulation of the powder properties of lamotrigine by crystal forms. *International Journal of Pharmaceutics*, **2021**, 595, 120274	6.5	2
44	Nanomechanical mapping and strain rate sensitivity of microcrystalline cellulose. *Journal of Materials Research*, **2021**, 36, 2251-2265	2.5	6
43	Improving the Physicochemical and Biopharmaceutical Properties of Active Pharmaceutical Ingredients Derived from Traditional Chinese Medicine through Cocrystal Engineering.. *Pharmaceutics*, **2021**, 13,	6.4	4
42	Mitigating Punch Sticking Propensity of Celecoxib by Cocrystallization: An Integrated Computational and Experimental Approach. *Crystal Growth and Design*, **2020**, 20, 4217-4223	3.5	14

41	Molecular Origin of the Distinct Tabletability of Loratadine and Desloratadine: Role of the Bonding Area - Bonding Strength Interplay. *Pharmaceutical Research*, **2020**, 37, 133	4.5	2
40	Reducing the Sublimation Tendency of Ligustrazine through Salt Formation. *Crystal Growth and Design*, **2020**, 20, 2057-2063	3.5	4
39	Simultaneous taste-masking and oral bioavailability enhancement of Ligustrazine by forming sweet salts. *International Journal of Pharmaceutics*, **2020**, 577, 119089	6.5	8
38	Extended Release of Highly Water Soluble Isoniazid Attained through Cocrystallization with Curcumin. *Crystal Growth and Design*, **2020**, 20, 1951-1960	3.5	19
37	The landscape of mechanical properties of molecular crystals. *CrystEngComm*, **2020**, 22, 1149-1153	3.3	48
36	Molecular Interpretation of Mechanical Behavior in Four Basic Crystal Packing of Isoniazid with Homologous Cocrystal Formers. *Crystal Growth and Design*, **2020**, 20, 832-844	3.5	8
35	Microstructures and pharmaceutical properties of ferulic acid agglomerates prepared by different spherical crystallization methods. *International Journal of Pharmaceutics*, **2020**, 574, 118914	6.5	14
34	Molecular Interpretation of the Compaction Performance and Mechanical Properties of Caffeine Cocrystals: A Polymorphic Study. *Molecular Pharmaceutics*, **2020**, 17, 21-31	5.6	8
33	Tabletability Flip - Role of Bonding Area and Bonding Strength Interplay. *Journal of Pharmaceutical Sciences*, **2020**, 109, 3569-3573	3.9	6
32	Development of piroxicam mini-tablets enabled by spherical cocrystallization. *International Journal of Pharmaceutics*, **2020**, 590, 119953	6.5	7
31	The efficient development of a sildenafil orally disintegrating tablet using a material sparing and expedited approach. *International Journal of Pharmaceutics*, **2020**, 589, 119816	6.5	5
30	Discovery, Characterization, and Pharmaceutical Applications of Two Loratadine–Oxalic Acid Cocrystals. *Crystals*, **2020**, 10, 996	2.3	0
29	Novel Quasi-Emulsion Solvent Diffusion-Based Spherical Cocrystallization Strategy for Simultaneously Improving the Manufacturability and Dissolution of Indomethacin. *Crystal Growth and Design*, **2020**, 20, 6752-6762	3.5	9
28	Crystallographic and Energetic Insights into Reduced Dissolution and Physical Stability of a Drug-Surfactant Salt: The Case of Norfloxacin Lauryl Sulfate. *Molecular Pharmaceutics*, **2020**, 17, 579-587	5.6	2
27	Fast Determination of Phase Stability of Hydrates Using Intrinsic Dissolution Rate Measurements. *Crystal Growth and Design*, **2019**, 19, 5471-5476	3.5	7
26	Developing Biologics Tablets: The Effects of Compression on the Structure and Stability of Bovine Serum Albumin and Lysozyme. *Molecular Pharmaceutics*, **2019**, 16, 1119-1131	5.6	9
25	Relationship between hydrate stability and accuracy of true density measured by helium pycnometry. *International Journal of Pharmaceutics*, **2019**, 567, 118444	6.5	8
24	Cocrystal Engineering of Itraconazole with Suberic Acid via Rotary Evaporation and Spray Drying. *Crystal Growth and Design*, **2019**, 19, 2736-2745	3.5	21

23	Computational Techniques for Predicting Mechanical Properties of Organic Crystals: A Systematic Evaluation. *Molecular Pharmaceutics*, **2019**, 16, 1732-1741	5.6	38
22	Reduced Punch Sticking Propensity of Acesulfame by Salt Formation: Role of Crystal Mechanical Property and Surface Chemistry. *Molecular Pharmaceutics*, **2019**, 16, 2700-2707	5.6	13
21	Robust bulk preparation and characterization of sulfamethazine and saccharine salt and cocrystal polymorphs. *CrystEngComm*, **2019**, 21, 2089-2096	3.3	15
20	Single-Crystal Plasticity Defies Bulk-Phase Mechanics in Isoniazid Cocrystals with Analogous Coformers. *Crystal Growth and Design*, **2019**, 19, 4465-4475	3.5	5
19	Structural Features of Sulfamethizole and Its Cocrystals: Beauty Within. *Crystal Growth and Design*, **2019**, 19, 7185-7192	3.5	9
18	Profoundly Improved Plasticity and Tabletability of Griseofulvin by in Situ Solvation and Desolvation during Spherical Crystallization. *Crystal Growth and Design*, **2019**, 19, 2350-2357	3.5	13
17	Spherical Cocrystallization: An Enabling Technology for the Development of High Dose Direct Compression Tablets of Poorly Soluble Drugs. *Crystal Growth and Design*, **2019**, 19, 2503-2510	3.5	12
16	Mechanism for the Reduced Dissolution of Ritonavir Tablets by Sodium Lauryl Sulfate. *Journal of Pharmaceutical Sciences*, **2019**, 108, 516-524	3.9	16
15	Identifying Slip Planes in Organic Polymorphs by Combined Energy Framework Calculations and Topology Analysis. *Crystal Growth and Design*, **2018**, 18, 1909-1916	3.5	48
14	Preparation, Characterization, and Formulation Development of Drug-Drug Protic Ionic Liquids of Diphenhydramine with Ibuprofen and Naproxen. *Molecular Pharmaceutics*, **2018**, 15, 4190-4201	5.6	26
13	Lack of dependence of mechanical properties of baicalein cocrystals on those of the constituent components. *CrystEngComm*, **2018**, 20, 5486-5489	3.3	8
12	Anion Exchange Reaction for Preparing Acesulfame Solid Forms. *Crystal Growth and Design*, **2018**, 18, 4215-4219	3.5	13
11	Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: an in vitro investigation. *International Journal of Food Sciences and Nutrition*, **2017**, 68, 704-711	3.7	42
10	Relationships among Crystal Structures, Mechanical Properties, and Tableting Performance Probed Using Four Salts of Diphenhydramine. *Crystal Growth and Design*, **2017**, 17, 6030-6040	3.5	42
9	Expedited development of a high dose orally disintegrating metformin tablet enabled by sweet salt formation with acesulfame. *International Journal of Pharmaceutics*, **2017**, 532, 435-443	6.5	28
8	Expedited Development of Diphenhydramine Orally Disintegrating Tablet through Integrated Crystal and Particle Engineering. *Molecular Pharmaceutics*, **2017**, 14, 3399-3408	5.6	17
7	Enhancing Bioavailability of Dihydromyricetin through Inhibiting Precipitation of Soluble Cocrystals by a Crystallization Inhibitor. *Crystal Growth and Design*, **2016**, 16, 5030-5039	3.5	56
6	Sweet Berberine. *Crystal Growth and Design*, **2016**, 16, 933-939	3.5	54

5	Solid-state characterization of optically pure (+)Dihydromyricetin extracted from Ampelopsis grossedentata leaves. *International Journal of Pharmaceutics*, **2016**, 511, 245-252	6.5	27
4	Preparation, characterization and in vivo studies of amorphous solid dispersion of berberine with hydrogenated phosphatidylcholine. *European Journal of Pharmaceutical Sciences*, **2015**, 74, 11-7	5.1	24
3	Deconvolution of the gene expression profiles of valuable banked blood specimens for studying the prognostic values of altered peripheral immune cell proportions in cancer patients. *PLoS ONE*, **2014**, 9, e100934	3.7	5
2	Exceptional Powder Tabletability of Elastically Flexible Crystals. *Crystal Growth and Design*,	3.5	1
1	An Elusive DrugDrug Cocrystal Prepared Using a Heteroseeding Strategy. *Crystal Growth and Design*,	3.5	3